Skip to main content
Equibles
PTPI logo

PTPI · Petros Pharmaceuticals, Inc.

Track PTPI — free

Use PTPI with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.05 -0.02 (-28.79%) At close · May 22
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the Company does not have sufficient resources to fund its operations for the next twelve months from the date of this filing, management has substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$169,489
Shares
42.37M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.05 Open$0.02 Day$0.02–0.06 Since split$0.05–0.27 Avg vol since split · 16d38.3M Short int754 · 0.0% float · 1.0d Short vol52% DataMay 2025–May 2025 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on May 1, 2025; bars on opposite sides are not compared.

The closing range begins at the captured split on May 1, 2025.

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.11M
Trailing 12 months
Net income (TTM)
−$3.20M
Trailing 12 months
Revenue growth YoY
-12.2%
Year over year
Operating margin
-90.5%
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 18,468.1%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+82.8%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Limited Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
RSI (14) 13
oversold
52-week position 0%
near low
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+60% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
16 holders — mid 3-yr range
Fundamentals
Fair
Revenue growth −12%
Y/Y
Gross margin 76%
expanding
EPS growth +98%
Y/Y
Free cash flow $-6.8M
Quant / Vol
risk profile
Very High
Volatility 252%
annualized · 1-yr
Max drawdown −83%
past year
ATR 102.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
1 · 2 · 0
50 / 200-day cross
No cross Neutral
RSI (14)
13 Neutral
52-week position
0% Bearish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+60% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
16 holders — mid 3-yr range
Price context
position in its range since split · 2025-05-01
Range low $0 Now $0 · 0% Range high $0

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PTPI
Petros Pharmaceuticals, Inc.
this stock
$169,489 — -12.2% — 0.0%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $66.37B — — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $58.66B +18.2% — — 0.1%
GALDY
Galderma Group AG/ADR
 $47.69B -1.7% — — 0.0%
HLN
Haleon plc
 $44.35B -2.0% — — 0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
16
% held
0.1%
Net QoQ
+41.3K sh
Top holder
JANE STREET GROUP, LLC
Held Float
View
Short & Settlement
Short Interest
Shares short
754
Days to cover
1.0d
Change
0 sh
View
Short Volume
Short vol %
52%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
2
Value
$0
As of
Apr 15, 2026
View
Off-Exchange
Off-exchange %
35.8%
Week of
May 19, 2025
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$5.1M
Net income (FY)
$1.9M
EPS diluted
$-1.56
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 13, 2026
This year
6
View
Exempt Offerings
Offering
$30.0M
Filed
Jul 21, 2023
View

Performance

Raw-price comparisons begin at the captured split on May 1, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
PTPI -70.6% — — — —
SPY -1.3% +6.7% -2.9% +5.2% -0.5%
vs SPY -69.4% — — — —
Key facts CIK 1815903 CUSIP 71678J308 Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)